糖尿病管理数字工具的作用、潜在效益和成本效益。

IF 3.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-06-09 DOI:10.1016/j.clinthera.2025.05.002

Anders L. Carlson MD , Sameer Badlani MD , Viral N. Shah MD

{"title":"糖尿病管理数字工具的作用、潜在效益和成本效益。","authors":"Anders L. Carlson MD , Sameer Badlani MD , Viral N. Shah MD","doi":"10.1016/j.clinthera.2025.05.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Health and financial burdens associated with poorly managed diabetes are considerable both for individuals and for healthcare systems. The last decade has seen a significant increase in the use of automated insulin delivery systems, continuous glucose monitoring and insulin pumps. With this, digital healthcare tools — such as smart or connected insulin pens and wearable continuous glucose monitoring (CGM) sensors utilizing current digital smartphone and wireless technology have emerged — helping people with diabetes and their healthcare providers maximize treatment adherence and achieve optimal glycemic control. This article reviews the available literature to assess current unmet needs within diabetes care management, summarizes the efficacy and safety of the latest US Food and Drug Administration (FDA)-approved insulin delivery systems and digital diabetes healthcare tools, and investigate the economic and healthcare benefits of such FDA-approved digital healthcare tools for people with diabetes in the US.</div></div><div><h3>Methods</h3><div>Literature searches were conducted using PubMed for articles published between 2014 and 2023. Type of articles included were narrative reviews, systematic reviews, randomized controlled trials and cost-effectiveness analyses.</div></div><div><h3>Findings</h3><div>There are many insulin delivery systems and associated digital devices, CGMs and software applications that utilize wireless and smartphone technology available within the US that have published efficacy, safety and cost-benefit outcomes. The safety and efficacy of CGM and continuous subcutaneous insulin infusion (CSII) therapy are well established. In contrast, the evidence available for the most recent digital diabetes healthcare tools (e.g., smart or connected insulin pens) is relatively limited.</div></div><div><h3>Implications</h3><div>Despite the acknowledged cost-effectiveness of digital healthcare tools within diabetes care and potential associated cost savings for healthcare markets, there are limited numbers of clinical studies investigating the efficacy and safety of newer devices such as smart or connected insulin pens. Further research is needed to pave the way for integrating these devices more fully into diabetes management.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 8","pages":"Pages 638-648"},"PeriodicalIF":3.6000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Role, Potential Benefits and Cost-effectiveness of Digital Tools for Diabetes Management\",\"authors\":\"Anders L. Carlson MD , Sameer Badlani MD , Viral N. Shah MD\",\"doi\":\"10.1016/j.clinthera.2025.05.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Health and financial burdens associated with poorly managed diabetes are considerable both for individuals and for healthcare systems. The last decade has seen a significant increase in the use of automated insulin delivery systems, continuous glucose monitoring and insulin pumps. With this, digital healthcare tools — such as smart or connected insulin pens and wearable continuous glucose monitoring (CGM) sensors utilizing current digital smartphone and wireless technology have emerged — helping people with diabetes and their healthcare providers maximize treatment adherence and achieve optimal glycemic control. This article reviews the available literature to assess current unmet needs within diabetes care management, summarizes the efficacy and safety of the latest US Food and Drug Administration (FDA)-approved insulin delivery systems and digital diabetes healthcare tools, and investigate the economic and healthcare benefits of such FDA-approved digital healthcare tools for people with diabetes in the US.</div></div><div><h3>Methods</h3><div>Literature searches were conducted using PubMed for articles published between 2014 and 2023. Type of articles included were narrative reviews, systematic reviews, randomized controlled trials and cost-effectiveness analyses.</div></div><div><h3>Findings</h3><div>There are many insulin delivery systems and associated digital devices, CGMs and software applications that utilize wireless and smartphone technology available within the US that have published efficacy, safety and cost-benefit outcomes. The safety and efficacy of CGM and continuous subcutaneous insulin infusion (CSII) therapy are well established. In contrast, the evidence available for the most recent digital diabetes healthcare tools (e.g., smart or connected insulin pens) is relatively limited.</div></div><div><h3>Implications</h3><div>Despite the acknowledged cost-effectiveness of digital healthcare tools within diabetes care and potential associated cost savings for healthcare markets, there are limited numbers of clinical studies investigating the efficacy and safety of newer devices such as smart or connected insulin pens. Further research is needed to pave the way for integrating these devices more fully into diabetes management.</div></div>\",\"PeriodicalId\":10699,\"journal\":{\"name\":\"Clinical therapeutics\",\"volume\":\"47 8\",\"pages\":\"Pages 638-648\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0149291825001663\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825001663","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

目的：对个人和卫生保健系统而言，与管理不善的糖尿病相关的健康和经济负担都相当大。在过去十年中，自动胰岛素输送系统、连续血糖监测和胰岛素泵的使用显著增加。因此，利用当前数字智能手机和无线技术的智能或连接胰岛素笔和可穿戴式连续血糖监测（CGM）传感器等数字医疗工具已经出现，帮助糖尿病患者及其医疗服务提供者最大限度地坚持治疗并实现最佳血糖控制。本文回顾了现有文献，以评估当前糖尿病护理管理中未满足的需求，总结了最新美国食品和药物管理局（FDA）批准的胰岛素输送系统和数字糖尿病医疗工具的有效性和安全性，并调查了FDA批准的数字糖尿病医疗工具对美国糖尿病患者的经济和医疗效益。方法：使用PubMed检索2014 - 2023年发表的文献。纳入的文章类型为叙述性综述、系统综述、随机对照试验和成本效益分析。研究结果：在美国有许多胰岛素输送系统和相关的数字设备、cgm和软件应用程序，利用无线和智能手机技术，已经公布了疗效、安全性和成本效益结果。CGM和持续皮下胰岛素输注（CSII）治疗的安全性和有效性已得到证实。相比之下，最新的数字糖尿病医疗工具（例如，智能或连接胰岛素笔）的可用证据相对有限。含义：尽管数字医疗保健工具在糖尿病护理中具有公认的成本效益，并可能为医疗保健市场节省相关成本，但调查智能或连接胰岛素笔等新设备的有效性和安全性的临床研究数量有限。需要进一步的研究来为将这些设备更充分地整合到糖尿病管理中铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Role, Potential Benefits and Cost-effectiveness of Digital Tools for Diabetes Management

Purpose

Health and financial burdens associated with poorly managed diabetes are considerable both for individuals and for healthcare systems. The last decade has seen a significant increase in the use of automated insulin delivery systems, continuous glucose monitoring and insulin pumps. With this, digital healthcare tools — such as smart or connected insulin pens and wearable continuous glucose monitoring (CGM) sensors utilizing current digital smartphone and wireless technology have emerged — helping people with diabetes and their healthcare providers maximize treatment adherence and achieve optimal glycemic control. This article reviews the available literature to assess current unmet needs within diabetes care management, summarizes the efficacy and safety of the latest US Food and Drug Administration (FDA)-approved insulin delivery systems and digital diabetes healthcare tools, and investigate the economic and healthcare benefits of such FDA-approved digital healthcare tools for people with diabetes in the US.

Methods

Literature searches were conducted using PubMed for articles published between 2014 and 2023. Type of articles included were narrative reviews, systematic reviews, randomized controlled trials and cost-effectiveness analyses.

Findings

There are many insulin delivery systems and associated digital devices, CGMs and software applications that utilize wireless and smartphone technology available within the US that have published efficacy, safety and cost-benefit outcomes. The safety and efficacy of CGM and continuous subcutaneous insulin infusion (CSII) therapy are well established. In contrast, the evidence available for the most recent digital diabetes healthcare tools (e.g., smart or connected insulin pens) is relatively limited.

Implications

Despite the acknowledged cost-effectiveness of digital healthcare tools within diabetes care and potential associated cost savings for healthcare markets, there are limited numbers of clinical studies investigating the efficacy and safety of newer devices such as smart or connected insulin pens. Further research is needed to pave the way for integrating these devices more fully into diabetes management.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.